dc.contributor.author | Bruckmüller, Henrike | |
dc.contributor.author | Cascorbi, Ingolf | |
dc.date.accessioned | 2022-02-24T08:29:10Z | |
dc.date.available | 2022-02-24T08:29:10Z | |
dc.date.issued | 2021-07-18 | |
dc.description.abstract | It is widely accepted that both comedications and genetic factors
may contribute to variation of drug response. Clinical decision
support systems increasingly consider recommendations on drug–
drug interactions (DDIs) during electronic prescribing, and some
guidelines on drug–gene-interactions (DGI) have been implemented
in drug labels. Potentially synergistically or antagonistically acting
drug-drug-gene interactions (DDGIs) have hardly been considered.
This Perspective article highlights examples and the complexity
of DDGI, aiming to strengthen consideration into clinical decision
support. | en_US |
dc.identifier.citation | Bruckmüller, Cascorbi. Drug-Drug-Gene Interactions: A Call for Clinical Consideration. Clinical Pharmacology and Therapeutics. 2021;110(3):549-551 | en_US |
dc.identifier.cristinID | FRIDAID 1990383 | |
dc.identifier.doi | 10.1002/cpt.2348 | |
dc.identifier.issn | 0009-9236 | |
dc.identifier.issn | 1532-6535 | |
dc.identifier.uri | https://hdl.handle.net/10037/24121 | |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.relation.journal | Clinical Pharmacology and Therapeutics | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.title | Drug-Drug-Gene Interactions: A Call for Clinical Consideration | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |